KR20180015145A - 핵산-양이온성 중합체 조성물 및 그의 제조 및 사용 방법 - Google Patents

핵산-양이온성 중합체 조성물 및 그의 제조 및 사용 방법 Download PDF

Info

Publication number
KR20180015145A
KR20180015145A KR1020177034664A KR20177034664A KR20180015145A KR 20180015145 A KR20180015145 A KR 20180015145A KR 1020177034664 A KR1020177034664 A KR 1020177034664A KR 20177034664 A KR20177034664 A KR 20177034664A KR 20180015145 A KR20180015145 A KR 20180015145A
Authority
KR
South Korea
Prior art keywords
composition
nucleic acid
carbohydrate
cationic polymer
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020177034664A
Other languages
English (en)
Korean (ko)
Inventor
아브라함 호치버그
제니퍼 갈룰라
Original Assignee
이섬 리서치 디벨러프먼트 컴파니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이섬 리서치 디벨러프먼트 컴파니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. filed Critical 이섬 리서치 디벨러프먼트 컴파니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디.
Publication of KR20180015145A publication Critical patent/KR20180015145A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Dermatology (AREA)
  • Manufacturing & Machinery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020177034664A 2015-05-05 2016-05-05 핵산-양이온성 중합체 조성물 및 그의 제조 및 사용 방법 Ceased KR20180015145A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL23864315 2015-05-05
IL238643 2015-05-05
PCT/IL2016/050477 WO2016178233A1 (en) 2015-05-05 2016-05-05 Nucleic acid-cationic polymer compositions and methods of making and using the same

Publications (1)

Publication Number Publication Date
KR20180015145A true KR20180015145A (ko) 2018-02-12

Family

ID=56134418

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177034664A Ceased KR20180015145A (ko) 2015-05-05 2016-05-05 핵산-양이온성 중합체 조성물 및 그의 제조 및 사용 방법

Country Status (14)

Country Link
US (2) US20180154023A1 (enExample)
EP (1) EP3291799A1 (enExample)
JP (2) JP2018515479A (enExample)
KR (1) KR20180015145A (enExample)
CN (1) CN107735079A (enExample)
AU (1) AU2016258326A1 (enExample)
BR (1) BR112017023788A2 (enExample)
CA (1) CA2984879A1 (enExample)
IL (1) IL255254A0 (enExample)
MX (1) MX2017014060A (enExample)
PH (1) PH12017502216A1 (enExample)
RU (1) RU2017140065A (enExample)
SG (2) SG11201708760PA (enExample)
WO (1) WO2016178233A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018515479A (ja) * 2015-05-05 2018-06-14 イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブライ ユニバーシティー オブ エルサレム リミテッドＹｉｓｓｕｍ Ｒｅｓｅａｒｃｈ Ｄｅｖｅｌｏｐｍｅｎｔ Ｃｏｍｐａｎｙ Ｏｆ Ｔｈｅ Ｈｅｂｒｅｗ Ｕｎｉｖｅｒｓｔｙ Ｏｆ Ｊｅｒｕｓａｌｅｍ Ｌｔｄ． 核酸−カチオン性ポリマー組成物、並びにその作製方法及び使用方法
DE102017003004A1 (de) 2017-03-23 2018-09-27 Friedrich-Schiller-Universität Jena Kationische Polymere mit D-Fructose-Substituenten
US10849921B2 (en) * 2017-05-17 2020-12-01 Bioncotech Therapeutics Sl Pharmaceutical composition comprising particles comprising a complex of a double-stranded polyribonucleotide and a polyalkyleneimine
EP3924463A1 (en) 2019-02-11 2021-12-22 Excellgene SA Novel eukaryotic cell transfection systems and related methods
CN111363761A (zh) * 2020-03-17 2020-07-03 苏州吉恒基因科技有限公司 利用阳离子多聚体dna复合物促进aav介导的基因表达方法
CA3181339A1 (en) * 2020-04-27 2021-11-04 Juno Therapeutics, Inc. Stabilization of polyethyleneimine-deoxyribonucleic acid complex size and activity
TW202228727A (zh) * 2020-10-01 2022-08-01 德商拜恩迪克公司 適用於治療之微脂體ｒｎａ調配物之製備及儲存
WO2022249180A1 (en) 2021-05-25 2022-12-01 Ramot At Tel-Aviv University Ltd. Compositions comprising extracellular vesicles and an active agent and uses thereof
CN113501889A (zh) * 2021-07-06 2021-10-15 郑州大学 一种三七多糖阳离子衍生物的制备方法及其应用
CN116549626A (zh) * 2022-01-27 2023-08-08 深圳瑞吉生物科技有限公司 一种载核酸脂质纳米颗粒冻干制剂及其制备方法与应用
CN114762731B (zh) * 2022-05-16 2024-08-23 常州大学 一种延长基因药物在温和条件下储存时间的方法
CN116036043A (zh) * 2023-01-10 2023-05-02 深圳市乐土生物医药有限公司 一种核酸药物制剂、冻干粉及制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
FR2722506B1 (fr) 1994-07-13 1996-08-14 Rhone Poulenc Rorer Sa Composition contenant des acides nucleiques, preparation et utilisations
US6087164A (en) * 1997-10-03 2000-07-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods and compositions for inducing tumor-specific cytotoxicity
US20040142474A1 (en) * 2000-09-14 2004-07-22 Expression Genetics, Inc. Novel cationic lipopolymer as a biocompatible gene delivery agent
WO2007007317A1 (en) 2005-07-07 2007-01-18 Yissum Research Development Company Of The Hebrew University Of Jerusalem Nucleic acid agents for downregulating h19, and methods of using same
JP2009508516A (ja) 2005-09-22 2009-03-05 イッサム リサーチ ディベロプメント カンパニー オブ ザ ヘブリュー ユニバーシティ オブ エルサレム 核酸構築物、薬剤組成物、及び癌治療のためのその使用方法
CA2675967A1 (en) 2007-01-16 2008-07-24 Yissum Research Development Company Of The Hebrew University Of Jerusale M Nucleic acid constructs and methods for specific silencing of h19
US20090042825A1 (en) * 2007-08-06 2009-02-12 Majed Matar Composition, method of preparation & application of concentrated formulations of condensed nucleic acids with a cationic lipopolymer
CN101820864A (zh) * 2007-08-06 2010-09-01 艾根股份有限公司 核酸-脂聚合物组合物
BRPI0818937B8 (pt) 2007-10-25 2021-05-25 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd constructos contendo múltiplos cassetes de expressão para terapia de câncer
WO2010028093A2 (en) * 2008-09-03 2010-03-11 Senesco Technologies, Inc. Use of a truncated elf-5a1 polynucleotide to induce apoptosis in cancer cells
DE102009006606A1 (de) * 2009-01-29 2010-08-05 Philipps-Universität Marburg Nicht-virales Transfektionsmittel
JP2018515479A (ja) * 2015-05-05 2018-06-14 イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブライ ユニバーシティー オブ エルサレム リミテッドＹｉｓｓｕｍ Ｒｅｓｅａｒｃｈ Ｄｅｖｅｌｏｐｍｅｎｔ Ｃｏｍｐａｎｙ Ｏｆ Ｔｈｅ Ｈｅｂｒｅｗ Ｕｎｉｖｅｒｓｔｙ Ｏｆ Ｊｅｒｕｓａｌｅｍ Ｌｔｄ． 核酸−カチオン性ポリマー組成物、並びにその作製方法及び使用方法

Also Published As

Publication number Publication date
IL255254A0 (en) 2017-12-31
EP3291799A1 (en) 2018-03-14
US20200138977A1 (en) 2020-05-07
US20180154023A1 (en) 2018-06-07
RU2017140065A (ru) 2019-06-05
BR112017023788A2 (pt) 2018-10-16
CN107735079A (zh) 2018-02-23
MX2017014060A (es) 2018-07-06
CA2984879A1 (en) 2016-11-10
JP2021130671A (ja) 2021-09-09
AU2016258326A1 (en) 2017-11-23
WO2016178233A1 (en) 2016-11-10
RU2017140065A3 (enExample) 2019-09-27
SG11201708760PA (en) 2017-11-29
PH12017502216A1 (en) 2018-06-11
JP2018515479A (ja) 2018-06-14
SG10201909209RA (en) 2019-11-28

Similar Documents

Publication Publication Date Title
US20200138977A1 (en) Nucleic acid-cationic polymer compositions and methods of making and using the same
Zhao et al. Long-term storage of lipid-like nanoparticles for mRNA delivery
Li et al. Ionizable lipid-assisted efficient hepatic delivery of gene editing elements for oncotherapy
Aranda-Barradas et al. Effect of molecular weight of chitosan on the physicochemical, morphological, and biological properties of polyplex nanoparticles intended for gene delivery
Lai et al. Nucleic acid delivery with chitosan and its derivatives
Meyer et al. A scalable and robust cationic lipid/polymer hybrid nanoparticle platform for mRNA delivery
Kaur et al. Modified mRNA as a therapeutic tool for the heart
CA2695901C (en) Nucleic acid-lipopolymer compositions
Ito et al. DNA/polyethyleneimine/hyaluronic acid small complex particles and tumor suppression in mice
Kang et al. Polymeric nucleic acid carriers: current issues and novel design approaches
Yan et al. Nanomedicine for gene delivery for the treatment of cardiovascular diseases
JP2015501791A (ja) 新規な遺伝子伝達用組成物
Gwak et al. Physicochemical stability and transfection efficiency of cationic amphiphilic copolymer/pDNA polyplexes for spinal cord injury repair
Jurgielewicz et al. Therapeutic potential of nucleic acids when combined with extracellular vesicles
Gwak et al. Multifunctional nanoparticles for gene delivery and spinal cord injury
CN114206906A (zh) Peg化的合成kl4肽、其组合物和方法
Zhou et al. Polyplex nanovesicles of single strand oligonucleotides for efficient cytosolic delivery of biomacromolecules
JP2002517519A (ja) エレクトロポレーション用製剤
Duskunovic et al. Effective mRNA delivery by condensation with cationic nanogels incorporated into liposomes
JP2022524859A (ja) キトサン－核酸ナノ粒子の可逆的コーティング及びその使用方法
CN109890393A (zh) 功能rna和小分子药物治疗性复合物和纳米颗粒递送媒介
JP6763780B2 (ja) 合成脳浸透遺伝子ベクターの操作
HK1247839A1 (en) Nucleic acid-cationic polymer compositions and methods of making and using the same
CN117460537A (zh) 核酸递送
Singh et al. The Junction of Biomaterials and Gene Therapy–Current Strategies and Future Directions

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000